I read more of the original "Theralase® Demonstrates Significant Advantage in Treatment of Brain Tumours" report and it is unbelievable there isn't more excitement on the board. The report makes comparisons between Theralase's Rutherrin(R) versus clinically approved PDC Amino Levulinic Acid ("ALA"). From the report:
"Further research conducted by Theralase researchers has demonstrated that Rutherrin® is able to provide a significant (up to 400 %) improvement in survival in animals treated with Rutherrin® versus IV injection of ALA and subsequent laser light activation."
The report goes on:
"Theralase researchers have also observed an increased number of anti-tumour specific immune cells in brain tissue treated with Rutherrin® versus ALA treated animals. This is quantified by observing the density of intratumoural, anti-cancer CD8+ T cells in GBM tumors.
"Clinical case studies of various cancers have demonstrated an increased survival in patients who possess a high density of intratumoural, anti-cancer CD8+ T cells in their respective tumours. It has been reported that an elevated level of tumour-infiltrating immune cells, such as anti-cancer CD8+ T cells, correlate with prolonged survival in GBM patients." (Justyna Kmiecik et. al Journal of Neuroimmunology 264 (2013) 71–83).
Consider the following:
"There are an estimated 24,000 new cases of malignant gliomas diagnosed in the US annually, with more than 14,000 deaths."
and:
"Terminally ill patients will be eligible for experimental drug therapies under a new Right to Try bill recently signed into law in the USA. Under this bill, we could potentially speed up clinical development of Rutherrin® for the treatment of life-threatening brain cancers.”
I an very excided regarding the future of Theralase Technologies Inc. Have a good evening everyone.
